Background: We tested the activity of BAL30072, a novel siderophore monobactam, against multiresistant clinical isolates of Pseudomonas aeruginosa, Burkholderia cepacia group and Acinetobacter spp. and against laboratory P. aeruginosa strains with defined resistance mechanisms.
Introduction
Drug resistance is frequent among clinical non-fermenters, most importantly Acinetobacter baumannii, Pseudomonas aeruginosa and species belonging to the Burkholderia cepacia complex. 1 In the case of A. baumannii, clones resistant to all antibiotics except polymyxin and (more variably) tigecycline are circulating in many countries, often affecting multiple hospitals. 2 Most of their resistance reflects acquired genes, but also involves up-regulation of endogenous ampC and bla OXA-51-like b-lactamase genes by insertion sequences, notably ISAba-1 . 3,4 In the case of P. aeruginosa, resistance to multiple antibiotics is rare among bloodstream isolates in north-western Europe but is a greater problem in southern and eastern Europe, Asia and South America. 5, 6 Higher resistance rates are seen locally, even in northern Europe, among P. aeruginosa isolates from intensive care units and, especially, from cystic fibrosis (CF) patients, whose ineradicable infections are exposed to repeated rounds of antimicrobial pressure and where the mode of bacterial growth may be inimical to antimicrobial action. 1 Most resistance in P. aeruginosa is mutational, though some non-CF isolates have acquired genes, including those encoding metallo-carbapenemases capable of attacking all b-lactams except monobactams. 1, 7 B. cepacia complex isolates-which also are important in CF, but rarely elsewhere-are inherently resistant to aminoglycosides and polymyxins, with further resistance arising by up-regulation of efflux and b-lactamases. 8, 9 Activity is most often retained by meropenem, ceftazidime and co-trimoxazole.
We examined the activity of BAL30072 (Figure 1 ), 10 11 overwhelming resistance mechanisms that compromise other b-lactams.
Materials and methods

Organisms
The reference strains comprised: (i) laboratory mutants of P. aeruginosa varying in expression of ampC and oprD; (ii) P. aeruginosa PU21 transconjugants carrying a range of acquired b-lactamase types; and (iii) clinical isolates with graded levels of efflux-determined resistance to b-lactams. 12 The clinical strains comprised: (i) A. baumannii isolates with OXA and metallo-carbapenemases; (ii) P. aeruginosa with metallo-b-lactamases; and (iii) multi-resistant P. aeruginosa and B. cepacia complex isolates from CF with undefined mechanisms of resistance.
The clinical isolates were selected from submissions to the UK reference laboratory and were mostly received for investigation of resistance. As such, they comprised a biased sample, more resistant than the generality of isolates. In particular the A. baumannii collection heavily represented the OXA-23 clone 1 and SE clone lineages with OXA-23 and up-regulated OXA-51 carbapenemases, respectively. These clones are widespread in southern England, each recorded from .50 hospitals. 13 
Results
Carbapenem-resistant A. baumannii isolates
Two hundred A. baumannii were tested: 143 belonging to the OXA-23 clone 1 13 and 27 to the SE clone with ISAba1-up-regulated chromosomal OXA-51.
14 These were selected as being the most prevalent multiresistant A. baumannii clones in the UK. The remaining 30 acinetobacters were diverse in terms of clone and carbapenemase: 14 had OXA-23 enzyme, 9 had OXA-58, 4 had IMP-metallo-carbapenemases, 2 had OXA-40 and 1 had up-regulated OXA-51 (Table 1 ). All the OXA-23 clone 1 isolates were non-susceptible to aztreonam (MICs 32 mg/L and generally .128 mg/L), imipenem, meropenem and piperacillin/tazobactam at CLSI breakpoints 15 whereas the proportions non-susceptible among the SE clone and diverse isolates ranged from 87% -100%. Around 90% of MIC values of BAL30072 for the two major clones were clustered from 0.12 to 2 mg/L (modes, 0.5 mg/L), though a few from each clone were more resistant, with MICs up to and above 128 mg/L. MICs for the diverse isolates were more scattered, with no relationship between carbapenemase type and MICs of BAL30072; thus MICs for isolates with the OXA-23 enzyme ranged from 0.06 to 128 mg/L, those for isolates with OXA-58 from 0.5 to .128 mg/L and for those with IMP enzymes, from 2 to 32 mg/L.
Metallo-carbapenemase-producing P. aeruginosa MIC distributions for the 19 metallo-b-lactamase-producing P. aeruginosa isolates are shown in Table 1 : 14 had VIM-type enzymes, 3 had IMP types and 2 had uncategorized types. Eleven were susceptible to BAL30072 at 8 mg/L compared with 3 susceptible to aztreonam at 8 mg/L; 12 and 8 were susceptible to BAL30072 and aztreonam, respectively, at 16 mg/L. MICs of both monobactams for the remaining isolates ranged up to .128 mg/L, with no evident relationship between enzyme type and MIC, implying the presence of other unidentified mechanisms besides the metallo-enzymes. All the isolates were resistant to imipenem and meropenem at 8 mg/L; four counted as susceptible to piperacillin/tazobactam at the current CLSI breakpoint of 64 mg/L, though it should be added that this value is clinically and pharmacodynamically discredited. 16 None was susceptible to piperacillin/tazobactam at the EUCAST breakpoint of 16 mg/L.
CF isolates of P. aeruginosa and B. cepacia
Among the 50 CF P. aeruginosa, 88% were resistant to aztreonam 8 mg/L; 88% to imipenem 4 mg/L, 72% to meropenem 4 mg/L and 74% to piperacillin/tazobactam. MICs of BAL30072 were widely scattered: they were lower consistently than those of aztreonam but still .8 mg/L in 32/50 cases (64%) and .128 mg/L in 12 (24%) ( Table 1 ). Isolates with high-level resistance to aztreonam were the most resistant also to BAL30072. Thus, the geometric mean MIC of BAL30072 was 3. The activity of BAL30072 against CF isolates belonging to the B. cepacia complex was impressive, with 78% susceptible at 8 mg/L and 68% at 1 mg/L compared with only 22% susceptible to aztreonam 8 mg/L (Table 1) ; nevertheless MICs were widely scattered, with no single mode and with some values 128 mg/L. The values seemed independent of species within the group, ranging from ,0.015 mg/L to .128 mg/L for both Burkholderia multivorans and B. cepacia species (not shown), though it was perhaps notable that six of eight isolates that could not be assigned to a species required MICs .8 mg/L 
P. aeruginosa reference strains and mutants
MICs of BAL30072 were 2 -4 mg/L for the AmpC-inducible and -deficient P. aeruginosa variants within the isogenic mutant series (Table 2) MICs of BAL30072 for the P. aeruginosa PU21 recipient were increased from 2 to 8 mg/L by OXA-2, -14 and -15 enzymes, though not by other OXA ESBLs (i.e. OXA-11 and -16), and to 32 mg/L by PER-1 enzyme (Table 2) . Aztreonam had its MICs raised 4-fold by OXA-10 and all its ESBL derivatives (OXA-11, -14 and -16), and also by OXA-15 enzyme (though not by its parent, OXA-2) and by OXA-6 b-lactamase; once again, PER-1 enzyme conferred greater resistance (MIC .128 mg/L).
MICs were determined for 87 P. aeruginosa isolates varying in 'intrinsic' resistance to b-lactams, but without derepressed AmpC or acquired b-lactamases. Previous studies indicate that their Mushtaq et al.
resistance was largely efflux determined. 17 MICs of BAL30072 rose with those of aztreonam, piperacillin/tazobactam and meropenem, implying that BAL30072 too is affected by efflux whereas MICs of imipenem, predictably, were less related (Table 3 ).
Discussion
Infections due to non-fermentative Gram-negative opportunists often present treatment problems, owing to multiresistance. 1 Recent years have seen a proliferation of carbapenem-resistant A. baumannii, most of them also resistant to other b-lactams, aminoglycosides and quinolones, whilst P. aeruginosa with panresistance to antibiotics except polymyxins have become frequent in CF and are scattered in other settings, particularly outside northern Europe and the USA.
1 B. cepacia complex isolates are rarer pathogens, but multiresistant strains are a problem in CF. Recently launched antibiotics offer only limited potential against these pathogens: tigecycline is active against some A. baumannii and B. cepacia but there are concerns about its low serum levels and disappointing Phase III trial results in ventilator-associated pneumonia;
18,19 doripenem offers a 2-fold gain in activity versus P. aeruginosa compared with meropenem but lacks activity against many CF isolates. It also lacks activity against A. baumannii or P. aeruginosa with OXA or metallo-carbapenamases. 12 Viewed against this disturbing background, the activity of BAL30072 against A. baumannii and B. cepacia is of considerable interest. At 8 mg/L the compound inhibited .93% of representatives of two carbapenemase-positive lineages, OXA-23 clone 1 and the SE clone, that are prevalent in the UK; 13, 14 it was active also against the great majority of CF B. cepacia complex isolates, regardless of species and resistance to other agents. Nevertheless, this activity was not universal, and resistance, with MICs ranging to .128 mg/L, was seen for a few A. baumannii, including a few representatives of the two major UK clones and a greater proportion of those belonging to other A. baumannii lineages, and in isolates of multiple species belonging to the B. cepacia complex. The reasons for this variability within clones that otherwise have a very consistent antibiogram (e.g. OXA-23 clone 1) are unclear. It was not related to carbapenemase type in A. baumannii (and the OXA carbapenemases do confer aztreonam resistance 20 ), nor to species within the B. cepacia complex. Since A. baumannii is extremely clonal and locally dominated by outbreak strains, it is likely that the utility of BAL30072 would vary significantly with locale, contingent on the particular clones dominant, exactly as with tigecycline, which is more active against OXA-23 clone 1 than against many other multiresistant lineages. BAL30072 versus non-fermenters 269 JAC BAL30072 had good activity against multiresistant P. aeruginosa too, although the differential compared with available agents was less striking than for A. baumannii and B. cepacia. Thus, among the CF P. aeruginosa isolates, 36% were susceptible to BAL30072 at 8 mg/L. Whilst this proportion is not immediately impressive, it should be stressed that these organisms were a highly selected reference laboratory collection and that the activity of BAL30072 was better than for any established comparator. MICs of BAL30072 were widely scattered for (non-CF) P. aeruginosa with metallo-carbapenemases, but with more isolates susceptible at 8-16 mg/L than for aztreonam. Although monobactams are stable to metallo-b-lactamases, 21 many producers have other resistance mechanisms, principally derepression of AmpC and/or up-regulated efflux, both of which affect BAL30072 as well as aztreonam. Various OXA ESBLs and the PER-1 enzyme also raised MICs of BAL30072 but these remain extremely rare except maybe in Turkey. 22, 23 In summary, BAL30072 has potential against problem nonfermenters, particularly some A. baumannii clones, and isolates belonging to the B. cepacia complex, with significantly greater activity than the b-lactam antibiotics used here as comparators. In view of its activity against B. cepacia it deserves evaluation also against Burkholderia pseudomallei.
